Early test of potential new obesity shots begins
NCT ID NCT07230496
Summary
This early-stage study is checking the safety and how the body processes two new injectable drugs, LAE103 and LAE102, in healthy overweight or obese adults and postmenopausal women. Researchers will give single and multiple doses to about 104 participants to see how well they are tolerated and how they move through the body. The main goal is to find a safe dose range for future testing, not to treat obesity in this trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Q-Pharm Pty Ltd.
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.